anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We aim to explore the potential of music therapy to support burnout among nurses and convenience sampling method will be adopted. This will be a randomized single-blinded, two-arm, parallel study, with data to be collected between August to December 2020. Eligible participants will be assigned to either music therapy group or the waiting-list control group. This study will be submitted to Leroj Atama Memorial Hospital at the Ministry of Health and Human Services and the College of the Marshall Islands Research committee for approval.We will enroll nurses from the General units of Leroj Atama Memorial Hospital in Majuro, Marshall Islands. The invitation to participate will be communicated by the Chief Nursing Officer and baseline assessment will be given by a trained study interviewer for participant recruitment. A structured questionnaire will be used to collect data on demographics, burnout, depression, stress, and anxiety. Participants will be recruited from the emergency units and 5 inpatients wards of general hospital of Leroj Atama Memorial Hospital in Majuro, Marshall Islands. We anticipate to enroll 42 nurses into this study. They will be divided into 2 group which are 21 for music group and 21 for control group.Random assignment will be performed by generating sequential numbers using computer software. The random sequential number will then be sealed in thick, opaque, consecutively numbered envelopes before data collections by an independent investigator. Patients will be allocated to either intervention or control group depending on the sequences number revealed by principal investigator. all participants in the music group will receive music intervention over five weeks. Each participant receives music intervention 30 mins per session (2 pm or 4 pm), three days in a week according to their schedule. Music intervention will be conducted at a quiet environment (i.e., nursing lounge) in the hospital. Four types of music protocols based on different rhythm or tones will provide to them, such as classical, slow music, traditional, and Christian song, before the session. Participants will listen to the songs selected and be given mp3 and earpiece for delivering the intervention. During each music session, individual will be advised to close his/her eyes and relaxed and only think of a happy memory. Participant in the waiting-list control group will be asked to maintain their daily routine and they will receive music intervention after the completion of the study.
Persons post stroke were first familiarized with the four exercise conditions and then instrumented with a metabolic system and heart rate sensor. They played the games in two counter balanced blocks: repeated (standard of care and self-paced repeated custom) and random (Microsoft-Kinect game and game-paced random custom). Games were played for 8.5 minutes with ten minutes of rest in between so they could return to physiological baseline. During exercise they reported exertion and at the end of teach exercise trial they completed an enjoyment questionnaire. At the end of the first block, participants removed the metabolic system's mask and were assessed for motor recovery. Performances were video taped. At the end of data collection preferences for the activities were ranked and participants answered open ended questions. Data for neuromuscular and cardiovascular intensity, enjoyment and perceived effort were reduced and analyzed using a Repeated Measures Analysis of Variance (RMANOVA) with the appropriate post-hoc corrections. Where possible clinically meaningful changes were calculated.
BACKGROUND: Neuroimaging studies have revealed alterations in habenular (Hb) structure and functional connectivity (FC) in psychiatric conditions. The Hb plays a particularly critical role in regulating negative emotions, which trigger excessive food intake and obesity. However, obesity and weight loss intervention (i.e., laparoscopic sleeve gastrectomy [LSG])-associated changes in Hb structure and FC have not been studied.
METHODS: We used voxel-based morphometry analysis to measure changes in gray matter volume (GMV) in the Hb in 56 patients with obesity at pre-LSG and 12 months post-LSG and in 78 normal-weight (NW) control participants. Then, we conducted Hb seed-based resting-state FC (RSFC) to examine obesity-related and LSG-induced alterations in RSFC. Finally, we used mediation analysis to characterize the interrelationships among Hb GMV, RSFC, and behaviors.
RESULTS: Compared with NW participants, Hb GMV was smaller in patients at pre-LSG and increased at 12 months post-LSG to levels equivalent to that of NW; in addition, increases in Hb GMV were correlated with reduced body mass index (BMI). Compared with NW participants, pre-LSG patients showed greater RSFCs of the Hb-insula, Hb-precentral gyrus, and Hb-rolandic operculum and weaker RSFCs of the Hb-thalamus, Hb-hypothalamus, and Hb-caudate; LSG normalized these RSFCs. Decreased RSFC of the Hb-insula was correlated with reduced BMI, Yale Food Addiction Scale rating, and emotional eating; reduced hunger levels were correlated with increased RSFCs of the Hb-thalamus and Hb-hypothalamus; and reduced BMI and Yale Food Addiction Scale ratings were correlated with increased RSFCs of the Hb-thalamus and Hb-hypothalamus, respectively. The bidirectional relationships between Hb GMV and RSFC of the Hb-insula contributed to reduced BMI.
CONCLUSIONS: These findings indicate that LSG increased Hb GMV and that its related improvement in RSFC of the Hb-insula may mediate long-term benefits of LSG for eating behaviors and weight loss.
PURPOSE:To stereoselectively obtain the titled optically active substance in high efficiency, by using alpha-hydroxy-beta-acetyl-butyric acid methyl ester and 3- chloro-4-methoxybenzyl-triphenylphosphonium bromide as starting substances. CONSTITUTION:The alkyne compound of formula I is treated with a reducing agent and the resultant vinyl compound is treated with a methylation agent to obtain the methoxy compound of formula II. The product is treated with a reducing agent and then with an oxidizing agent to afford an alcohol of formula III. The primary alcohol is protected and then reduced to form the compound of formula IV (R is protective group for primary alcohol). The compound is made to react with the compound of formula V and the protecting group is removed to obtain the compound of formula VI, which is treated with John's reagent and converted to methyl ester with diazomethane. The ester is treated with a formylation agent and then converted to methyl ether with diazomethane to economically obtain the objective optically active compound (an antibiotic substance having strong antibacterial activity).
Population-based genomic screening may help diagnose individuals with disease-risk variants. Here, we perform a genome-first evaluation for nine disorders in 29,039 participants with linked exome sequences and electronic health records (EHRs). We identify 614 individuals with 303 pathogenic/likely pathogenic or predicted loss-of-function (P/LP/LoF) variants, yielding 644 observations; 487 observations (76%) lack a corresponding clinical diagnosis in the EHR. Upon further investigation, 75 clinically undiagnosed observations (15%) have evidence of symptomatic untreated disease, including familial hypercholesterolemia (3 of 6 [50%] undiagnosed observations with disease evidence) and breast cancer (23 of 106 [22%]). These genetic findings enable targeted phenotyping that reveals new diagnoses in previously undiagnosed individuals. Disease yield is greater with variants in penetrant genes for which disease is observed in carriers in an independent cohort. The prevalence of P/LP/LoF variants exceeds that of clinical diagnoses, and some clinically undiagnosed carriers are discovered to have disease. These results highlight the potential of population-based genomic screening.
OBJECTIVE: Posttraumatic stress disorder (PTSD) has been linked with menopause symptoms (eg, vasomotor, urinary) and their sequelae (eg, sexual difficulties). However, PTSD is a heterogeneous disorder, and less is known about which aspects may be most associated with menopause-related health.
METHODS: Using confirmatory factor analyses, we evaluated five structural models of PTSD symptoms in 208 predominately postmenopausal women veterans (aged 45-64 years). We investigated associations between PTSD-operationalized as a probable diagnosis and symptom dimensions of the best-fitting model-and common menopause-related health concerns, including (1) vasomotor, urinary, and vaginal symptoms; (2) vasomotor symptom interference; and (3) sexual functioning.
RESULTS: A six-factor anhedonia model-comprising re-experiencing, avoidance, negative affect, anhedonia, anxious arousal, and dysphoric arousal-provided optimal fit. Both probable PTSD and greater symptoms across all dimensions were linked with presence of urinary and vasomotor, but not vaginal, symptoms. Comparing dimensions revealed that negative affect and dysphoric arousal were particularly associated with urinary symptoms, whereas dysphoric arousal was the factor most strongly related to vasomotor symptom interference. Associations between PTSD and sexual dysfunction were mixed; whereas there was no relation with probable diagnosis, all dimensions were linked with adverse sexual sequelae.
CONCLUSIONS: PTSD-considered categorically and dimensionally-was relevant to menopause-related health in midlife women veterans. Further, symptoms of negative affect and dysphoric arousal were particularly related to urinary and vasomotor symptoms. These specific symptoms may drive associations between PTSD and these aspects of menopause-related health. Clinical interventions targeting these symptoms may promote midlife women's health.
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, namely to preparation for protection against chemical liver injury, increase of resistance to hypoxia, acceleration of ethanol removal in vivo and increase of ability to recovery and survival under conditions of absence of oxygen. Preparation for protection against chemical liver injury, increase of resistance to hypoxia, acceleration of ethanol removal in vivo and increase of ability to recovery and survival under conditions of absence of oxygen, which contains combination of composition (a), containing amino acids, including citrulline and ornithine hydrochloride; and composition (b), which contains mixture of ginseng extract, extract of ginkgo biloba leaves and silibinin extract, non-obligatorily with suitable filler, with each component being taken in specified quantity. Food preparation. Diet additive. Neutraceutic. Drink. Medication. Application of preparation for: protection against chemical liver injury, increase of resistance to hypoxia, acceleration of removal of ethanol in vivo, and increase of ability to recovery and survival under conditions of absence of oxygen. Method of treating or prevention of alcohol intoxication, chemical liver injury, increase of resistance to hypoxia, reduction of content of ethanol in vivo and increase of ability to recovery and survival under conditions of absence of oxygen.EFFECT: preparation, as well as said mediations on its basis are effective for protection against chemical liver injury, increase of resistance to hypoxia, acceleration of ethanol removal in vivo, and increase of ability to recovery and survival under conditions of absence of oxygen.22 cl, 17 tbl, 13 ex
A pharmaceutical compsn. for the treatment of HIV infections contains immunoglobulins and lower molecular substances with at least one organically bonded sulphide gp., as well as conventional carriers. The immunoglobulin is of class IgG, IgA, IgM and/or IgD. The IgG immunoglobulins are pref. of sub-class IgG 1-4, esp. IgG 2a and/or IgG 2b. The substance contg. sulphide gps. is glutathione or an N-ethanoyl cysteine deriv., esp. N-ethanoyl cysteine itself. USE/ADVANTAGE - The compsn. can be used for the treatment of HIV infections to activate the reticuloendothelial system which produces lymphocytes, monocytes and macrophages, and for long-lasting regulation of the T4/T8 ratio in the HIV infections. The compsn. can be used in the form of an aerosol, intrarectally, orally or topically.
Participants allocated to the CARMS therapy + TAU arm will receive their usual care and treatment from mental health services along with CARMS (Cognitive AppRoaches to coMbatting Suicidality) therapy. The CARMS therapy comprises of 24 sessions, each up to 50 minutes long over a 6 month period.
PROBLEM TO BE SOLVED: To obtain a hair tonic and a hair cosmetic, capable of promoting regeneration of hair and the growth of the hair in spare hair or alopecia by activating hair follicle by including an extract of the mycelium of Agaricus blazei Murill. SOLUTION: The hair tonic and hair cosmetic contain an extract of the mycelium of Agaricus blazei Murill and/or a filtrate of a liquid culturing the mycelium of the Agaricus blazei Murill. The Agaricus blazei Murill is a species belonging to the genus Agaricus of the family Agaricaceae of the order Agaricales in the kind Basidiomycetes, and also called 'Kawariharatake' and 'Himematsutake'. The Agaricus blazei Murill is spread out in the southeast part of North America, and South America, and is the one of mushroom used to be eaten by the inhabitant in the southeast part of Brazil. The Agaricus blazei Murill is deposited in Fermentation Research Institute, Agency of Industrial Science and Technology, as an accession no. FERM 4731. The culturing method of the Agaricus blazei Murill is preferably a liquid culturing method.
Background: During the Ebola epidemic of 2014-5, there was no proven therapy or prevention available beyond horizontal infection control measures. After the Canadian government donated 800 vials of the vaccine candidate VSV-EBOV to World Health Organization (WHO), the University Hospitals of Geneva agreed to perform a WHO-coordinated phase I/II double-blind, placebo-controlled randomized trial to assess the candidate's safety and immunogenicity healthy adult volunteers. The doses of 10 E7 pfu and 5 x 10 E7 pfu were tested in 35 and 16 volunteers, respectively, before a safety-driven study hold in late 2014. At trial resumption in early 2015, the remaining volunteers (n=51) received 3 x 10 E5 pfu. Thirteen volunteers received placebo. Among vaccinees, early immune responses were impressive, even at the lowest dose of 3 x 10 E5 pfu, and persisted well up to 6 months (last time point assessed). The trial successfully ended 12 months after injection. This prospective observational study will assess immune durability in this group of vaccinees at yearly time points up to five years post-vaccination.
Alcohol use disorders are among the top causes of the global burden of disease, yet therapeutic interventions are limited. Reduced desire to drink in patients treated with semaglutide has raised interest regarding its potential therapeutic benefits for alcohol use disorders. In this retrospective cohort study of electronic health records of 83,825 patients with obesity, we show that semaglutide compared with other anti-obesity medications is associated with a 50%-56% lower risk for both the incidence and recurrence of alcohol use disorder for a 12-month follow-up period. Consistent reductions were seen for patients stratified by gender, age group, race and in patients with and without type 2 diabetes. Similar findings are replicated in the study population with 598,803 patients with type 2 diabetes. These findings provide evidence of the potential benefit of semaglutide in AUD in real-world populations and call for further randomized clinicl trials.
Participants first received Avigan FT 200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favira 200 mg FT manufactured by Novelfarma in a fasting state.
The invention belongs to the field of traditional Chinese medicine preparations and relates to an Aidi temperature/pH-sensitive in-situ gel preparation and a preparation method thereof. The Aidi temperature/pH-sensitive in-situ gel preparation is prepared from Aidi extract, in-situ gel matrix acknowledged in the field and other pharmaceutically necessary auxiliary materials by the preparation method. The Aidi temperature/pH-sensitive in-situ gel preparation is liquid which can flow freely at a room temperature. After being taken by a patient, because of a temperature/pH change, the Aidi temperature/pH-sensitive in-situ gel preparation forms semisolid gel. The Aidi temperature/pH-sensitive in-situ gel preparation has the advantages of clear curative effects, stable properties, simple preparation, convenient administration method, strong compliance of patients, no toxic and side effects, no adverse effects and high bioavailability. The Aidi temperature/pH-sensitive in-situ gel preparation has functions of clearing heat, removing toxins, removing stasis and eliminating stagnation, and is suitable for treating a primary liver cancer, a lung cancer, a rectal cancer, a lymph cancer and gynecological cancers.
PROBLEM TO BE SOLVED: To obtain a tablet produced easily swallowable by aged person, baby, child, a patient having difficulty to swallow or a patient restricted in having water an being safe to swallow without causing choking, etc., by using a substance satisfying a specific condition. SOLUTION: This tablet exclusively contains one or more kinds of highly water-soluble solid drugs preferably satisfying the following conditions. The solubility in water at 20 deg.C is 0.1-3g/mL (especially 0.2-2g/mL); it keeps solid state at 50 deg.C (especially at 100 deg.C); the administration rate of the agent for adult is 100mg to 50g (especially 1-10g) per dose. The drug is especially preferably a sugar-based or sugar alcohol-based drug. The highly water-soluble solid drug is especially preferably lactinol, lactulose, moranoline, their anhydrides or hydrates. The quickly soluble tablet can be produced by compression-molding a kneaded composition essentially exclusively containing a highly water-soluble solid drug and water or a water-ethanol mixture and drying the molded product.
Each participant wore one CW2 sensor attached to the back of the wrist with a wrist band. Additionally, each participant wore a reference pulse oximeter (Nellcor PM10) attached to the middle finger of the ipsilateral hand. This enabled the comparison of the paired results of the CW2 sensor and reference pulse oximeter equipment for SpO2 measurements at different oxygen saturation levels. Twelve subjects of the 24 participants received an arterial catheter in the contralateral radial artery for exvivo SaO2 determination by CO-oximetry and in order to define the final accuracy of CW2 for SpO2 measurement.
PURPOSE:To obtain a shampoo and basic cosmetic containing an essence extracted from Ecklonia stolonifera Okamura as an ingredient and capable of imparting gloss, roundness an moistness to the skin. CONSTITUTION:A shampoo and basic cosmetic containing an essence extracted from Ecklonia stolonifera Okamura as an active ingredient. The Ecklonia stolonifera Okamura (especially with a low-molecular weight of about 500 molecular weight) is sufficiently dried, washed with water, then dried, finely cut to about 3-5cm width and subsequently converted into fine powder having about 100 mesh size. In a solution containing 10g sodium bicarbonate added to 1kg purified water, is dipped 100g aforementioned fine powder. To the resultant solution, is added 100g 1,3-butylene glycol and the obtained mixture is heated at 80 deg.C for 3hr. Furthermore, 2kg purified water is added thereto and digestion is carried out at 50 deg.C temperature for 24hr to filter the resultant extract solution twice in a hot state. The obtained filtrate is allowed to stand for 24hr to afford the objective essence containing alginates, polysaccharides and various amino acids.
This study will be carried out on patient data usually collected as part of their care. The patients were infected with COVID-19 and hospitalized between 03/25/2020 and 05/07/2020, and who benefited from GAREC's intervention.
Clinical studies of methenamine hippurate tablet, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Methenamine hippurate tablets, USP are contraindicated in patients with renal insufficiency and severe hepatic insufficiency. (see ). CONTRAINDICATIONS
IMPORTANCE: Urethral bulking is an alternative to synthetic midurethral sling for the treatment of stress urinary incontinence (SUI) in women. Urethral bulking agents, which are injected in the submucosal tissues of the proximal urethra/bladder neck, have demonstrated less adverse effects with similar satisfaction rates but lower subjective and objective cure rates when compared with midurethral sling. Cystoscopic Reconstruction of External Sphincter Technique (CREST) is a novel technique, which reinforces the natural closure mechanism of the external urinary sphincter (EUS).
OBJECTIVE: The aim of the study was to provide safety and efficacy data for injecting polyacrylamide hydrogel (PAHG) in the components of the female EUS.
STUDY DESIGN: This was a retrospective chart review of patients using CREST with PAHG as initial treatment for SUI by a single surgeon from January 2022 to October 2022. Exclusion criteria are as follows: younger than 18 years, prior SUI surgery, concomitant pelvic organ prolapse or reconstructive procedure, neurological conditions, or history of radiation. Subjective and objective cure rates were measured by patient-reported symptoms and cough stress test. Urinary retention, postoperative urinary infection, and de novo urinary urgency were assessed.
RESULTS: One hundred and thirteen consecutive patients met inclusion criteria with median follow-up of 3 months. Eighty-five percent of participants reported subjective improvement, 69% reported subjective cure, and 69% demonstrated objective cure. Nine patients reported transient postoperative retention, 8 reported postoperative urinary tract infections, and 5 reported de novo urgency. There were no serious adverse events.
CONCLUSIONS: CREST is a novel technique for injection of PAHG, into the EUS to treat SUI. Our data suggest that this technique could improve urethral injection outcomes with minimal complications.
Cyproheptadine HCl USP, is an antihistaminic and antiserotonergic agent.

Cyproheptadine hydrochloride USP is a white to slightly yellowish crystalline solid, with a molecular weight of 350.89, which is soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform, and practically insoluble in ether. It is the sesquihydrate of 4-(5 H\- dibenzo [a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride. The molecular formula of the anhydrous salt is C 21H 21N•HCl and the structural formula of the anhydrous salt is: 

C 21H 21N• HCl M.W. 350.89 

Cyproheptadine hydrochloride USP is available for oral administration in 4 mg tablets. Inactive ingredients include: lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.